{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:23:29Z","timestamp":1785813809379,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"DOI":"10.7759\/cureus.72725","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T20:43:31Z","timestamp":1730321011000},"source":"Crossref","is-referenced-by-count":3,"title":["The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Transthyretin Cardiac Amyloidosis: A Single-Center Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Ashwin","family":"Pillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeena","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark K","year":"2021","unstructured":"Lindmark K, Pilebro B, Sundstr\u00f6m T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021, 8:745-9. 10.1002\/ehf2.13110","journal-title":"ESC Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez E","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al.. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015, 36:2585-94. 10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap LG","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y, et al.. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019, 12:e005407. 10.1161\/CIRCHEARTFAILURE.118.005407","journal-title":"Circ Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha KM","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023, 5:82-90. 10.36628\/ijhf.2022.0030","journal-title":"Int J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri M","year":"2022","unstructured":"Zampieri M, Argir\u00f2 A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. 2022, 17:1243-5. 10.1007\/s11739-022-02944-8","journal-title":"Intern Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner S","year":"2023","unstructured":"Dobner S, Bernhard B, Asatryan B, et al.. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023, 10:397-404. 10.1002\/ehf2.14188","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.10.147","article-title":"Inhibition of sodium-glucose transport protein as a therapeutic option in the patients with transthyretin cardiac amyloidosis","volume":"30","author":"Riaz S","year":"2024","unstructured":"Riaz S, Pillai A, Lico I, Tysarowski M, Shaik A, Arora S, Jaiswal A. Inhibition of sodium-glucose transport protein as a therapeutic option in the patients with transthyretin cardiac amyloidosis. J Card Fail. 2024, 30:176-7. 10.1016\/j.cardfail.2023.10.147","journal-title":"J Card Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.17122","article-title":"Abstract 17122: Role of a dedicated program in early recognition and treatment of transthyretin cardiac amyloidosis","volume":"148","author":"Pillai A","year":"2023","unstructured":"Pillai A, Arora S, Jaiswal A. Abstract 17122: Role of a dedicated program in early recognition and treatment of transthyretin cardiac amyloidosis. Circulation. 2023, 148:17122. 10.1161\/circ.148.suppl_1.17122","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.08.009","article-title":"Urinary tract infections: core curriculum 2024","volume":"83","author":"Al Lawati H","year":"2024","unstructured":"Al Lawati H, Blair BM, Larnard J. Urinary tract infections: core curriculum 2024. Am J Kidney Dis. 2024, 83:90-100. 10.1053\/j.ajkd.2023.08.009","journal-title":"Am J Kidney Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin JM","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021, 128:1554-75. 10.1161\/CIRCRESAHA.121.318187","journal-title":"Circ Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-019-1299-1","article-title":"Cardiac amyloidosis: the need for early diagnosis","volume":"27","author":"Oerlemans MI","year":"2019","unstructured":"Oerlemans MI, Rutten KH, Minnema MC, Raymakers RA, Asselbergs FW, de Jonge N. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019, 27:525-36. 10.1007\/s12471-019-1299-1","journal-title":"Neth Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two decades of cardiac amyloidosis: A Danish Nationwide Study","volume":"3","author":"Westin O","year":"2021","unstructured":"Westin O, Butt JH, Gustafsson F, et al.. Two decades of cardiac amyloidosis: A Danish Nationwide Study. JACC CardioOncol. 2021, 3:522-33. 10.1016\/j.jaccao.2021.05.004","journal-title":"JACC CardioOncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, et al.. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023, 44:2893-907. 10.1093\/eurheartj\/ehad347","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer MS","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, et al.. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023, 389:1553-65. 10.1056\/NEJMoa2300757","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore JD","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al.. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024, 390:132-42. 10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)02677-9","article-title":"Guideline directed medical therapy reduces mortality in inotrope dependent heart failure patients","volume":"83","author":"Singh KS","year":"2024","unstructured":"Singh KS, Pillai AA, Shaik A, et al.. Guideline directed medical therapy reduces mortality in inotrope dependent heart failure patients. J Am Coll Cardiol. 2024, 83:687. 10.1016\/S0735-1097(24)02677-9","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)02673-1","article-title":"Sacubitril-valsartan prescription and tolerance among inotrope-dependent heart failure patients","volume":"83","author":"Singh KS","year":"2024","unstructured":"Singh KS, Pillai AA, Shaik A, et al.. Sacubitril-valsartan prescription and tolerance among inotrope-dependent heart failure patients. J Am Coll Cardiol. 2024, 83:683. 10.1016\/S0735-1097(24)02673-1","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni D","year":"2022","unstructured":"Tomasoni D, Fonarow GC, Adamo M, et al.. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022, 24:431-41. 10.1002\/ejhf.2397","journal-title":"Eur J Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari A","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, et al.. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024, 83:2411-22. 10.1016\/j.jacc.2024.03.429","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01464-6","article-title":"Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes","volume":"23","author":"Tanr\u0131verdi M","year":"2023","unstructured":"Tanr\u0131verdi M, Ba\u015ftemir M, Demirbakan H, \u00dcnalan A, T\u00fcrkmen M, Tanr\u0131verdi G\u00d6. Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr Disord. 2023, 23:211. 10.1186\/s12902-023-01464-6","journal-title":"BMC Endocr Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S40522","article-title":"Proteinuria and its relation to cardiovascular disease","volume":"7","author":"Currie G","year":"2013","unstructured":"Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2013, 7:13-24. 10.2147\/IJNRD.S40522","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","volume":"8","author":"Barrett CD","year":"2020","unstructured":"Barrett CD, Alexander KM, Zhao H, et al.. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail. 2020, 8:461-8. 10.1016\/j.jchf.2019.12.013","journal-title":"JACC Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2020.08.020","article-title":"Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience","volume":"53","author":"Chen Q","year":"2021","unstructured":"Chen Q, Moriguchi J, Levine R, et al.. Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience. Transplant Proc. 2021, 53:329-34. 10.1016\/j.transproceed.2020.08.020","journal-title":"Transplant Proc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt B","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al.. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023, 29:1412-51. 10.1016\/j.cardfail.2023.07.006","journal-title":"J Card Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2024.01.005","article-title":"Usage of older donors is associated with higher mortality after heart transplantation: a UNOS observational study","volume":"43","author":"Jaiswal A","year":"2024","unstructured":"Jaiswal A, Kittleson M, Pillai A, Baran D, Baker WL. Usage of older donors is associated with higher mortality after heart transplantation: a UNOS observational study. J Heart Lung Transplant. 2024, 43:806-15. 10.1016\/j.healun.2024.01.005","journal-title":"J Heart Lung Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007931","article-title":"Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS","volume":"13","author":"Michelis KC","year":"2020","unstructured":"Michelis KC, Zhong L, Tang WH, et al.. Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS. Circ Heart Fail. 2020, 13:e007931. 10.1161\/CIRCHEARTFAILURE.120.007931","journal-title":"Circ Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah SJ","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, et al.. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024, 9:25-34. 10.1001\/jamacardio.2023.4147","journal-title":"JAMA Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311459-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-adults-with-transthyretin-cardiac-amyloidosis-a-single-center-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T20:43:32Z","timestamp":1730321012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311459-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-adults-with-transthyretin-cardiac-amyloidosis-a-single-center-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.72725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}